Roivant Sciences and Janux Therapeutics Compared on Valuation and Risk
What happened
A comparison of Roivant Sciences and Janux Therapeutics contrasted the companies based on profitability, valuation, risk, and analyst recommendations. Janux Therapeutics reported higher revenue and earnings than Roivant Sciences, but Roivant Sciences trades at a lower price-to-earnings ratio. Janux Therapeutics has a beta of 2.4, indicating it is 140% more volatile than the S&P 500, while Roivant Sciences has a beta of 1.1.
From themarketsdaily.com
Why it matters
The comparison provides investors with metrics on risk and valuation for both healthcare companies. Janux Therapeutics has a consensus target price suggesting a potential upside of 98.27%, while Roivant Sciences has a consensus target price suggesting a potential upside of 28.77%.
From themarketsdaily.com
Who's involved
- Roivant Sciences (United States)Healthcare company subject to valuation and risk comparison
Keep exploring
The entities involved
-
Roivant Sciences (United States)
company in New York, United States